Newsletter · · Ashutosh Agarwal

FDA Clears an Alzheimer's Tau Scan and Lantheus Gets Bought - The Neuro & Alzheimer's Pipeline - Week of August 30, 2026

The Neuro & Alzheimer's Pipeline for the week of August 24 to 30, 2026. Podcast synthesis on the FDA clearing Lantheus's tau PET imaging agent days before Curium agreed to buy the company for roughly $8 billion, Eli Lilly's four-sided week with no mention of Kisunla, and researchers arguing that amyloid plaque may be part of the brain's own immune defense.

The Neuro & Alzheimer's Pipeline

Week of August 30, 2026: FDA Clears an Alzheimer's Tau Scan and Lantheus Gets Bought

Week of August 24 to August 30, 2026.

The podcasts finally handed this newsletter a real, dollars-and-cents event, and it is a good one. A company that makes brain-scan dyes just won an FDA approval for a new Alzheimer's tau scan, and within days agreed to sell itself for roughly $8 billion. It lands squarely on the theme this newsletter keeps circling: the field's slow pivot away from amyloid and toward tau.

Two notes on sourcing before we start. The one in-window show is an AI-generated markets recap, so treat its opinions as automated commentary rather than inside knowledge; the facts it reported are real, verifiable corporate events, checked independently. Three other episodes that surfaced are science-and-wellness shows dated August 20, just outside the week, and none carried company or drug-sales news, so they are thematic color and flagged as such in place.

(Quick vocabulary, used throughout. Amyloid and tau are the two toxic proteins that pile up in an Alzheimer's brain: amyloid clumps in the spaces between brain cells, tau forms tangles inside them. Today's approved drugs go after amyloid; the newer, riskier bets go after tau. A PET scan is a brain scan that uses a tiny amount of injected radioactive dye, a "tracer," to make one specific target light up so doctors can see it; an amyloid PET lights up amyloid, a tau PET lights up tau. The tau PET agent is that dye itself, and getting a good one approved matters, because you cannot easily run a tau-drug trial, or pick the right patients for it, without a reliable way to see tau in a living brain. A CVR (contingent value right) is a deal sweetener: on top of the cash, the buyer promises extra money later, but only if certain sales or milestones get hit, an IOU that pays only if things go well. ARIA is the brain-swelling-and-bleeding side effect that the amyloid drugs, Lilly's Kisunla and Eisai/Biogen's Leqembi, can cause.)

TL;DR

  • The Alzheimer's tau scan just got a stamp and a buyer. The FDA approved Lantheus's tau PET imaging agent (brand name TAUKLARIFY), and days later Curium agreed to buy Lantheus (LNTH) outright, about $102.50 a share in cash plus up to $12 more in milestone payments, roughly $8 billion, closing in the first half of 2027. It is the first hard corporate event this space has produced in weeks, and it is in the picks-and-shovels imaging layer, not the drugs.
  • Eli Lilly had a monster week, with zero of it about Kisunla. Lilly agreed to a roughly $800 million guilty plea over how it once marketed an old antipsychotic, bought three vaccine companies for $3.8 billion, signed a cancer-vaccine partnership, and raised full-year revenue guidance to $85 to $87 billion. Its Alzheimer's drug was not mentioned.
  • The "it's not just amyloid" case got louder. Two science podcasts argued that infections, poor blood flow, and hormones may be real drivers of Alzheimer's, and one made the provocative claim that amyloid plaque is partly the brain's immune defense, not just disease debris. No stock news, but it sharpens the bear case on the whole amyloid-clearing franchise.

What's new

The headline: Lantheus wins FDA approval for a tau brain scan, then agrees to sell itself for about $8 billion. On Telltales ("Weekend Update - W2634," Aug 23), a show that is entirely AI-generated (it says so itself), so weigh the commentary as an automated recap rather than human insight while the underlying facts are real, the hosts walked through a deal that matters to everyone reading this. Curium, a rival radiopharmaceutical company, agreed to acquire Lantheus (LNTH) for "$102.50 a share in cash, plus contingent value rights worth up to $12 more, for a total potential value around $8 billion, expected to close in the first half of 2027." The kicker: the agreement came "five days after the FDA approved [TAUKLARIFY], Lantheus' Tau PET imaging agent for identifying tau pathology in adults being evaluated for Alzheimer's." For the record, the correct trade name is TAUKLARIFY, generic florquinitau F 18, the tracer formerly known in trials as MK-6240; the FDA cleared it in mid-August. The hosts noted Lantheus "pulled its own full year guidance when the agreement was signed, which is what a company does when the forecast stops being its decision." Why it moves numbers: this is two things at once. First, there is now a brand-new, FDA-approved way to see tau in a living brain, exactly the infrastructure the tau-drug pivot has been waiting for. Second, one of this newsletter's recurring read-through names is about to disappear into a private acquirer, so the public way to own the Alzheimer's-imaging story just got smaller.

The valuation the hosts kept hammering: Lantheus was cheap, clean, and still got a premium. Same episode: the show pegged Lantheus at "12 times trailing free cash flow, with essentially no debt against it," throwing off "roughly an 8% free cash flow yield," and said Curium "is paying about 15 times that trailing cash flow to take the whole thing out." Because the deal does not close until 2027, the stock is still trading below the $102.50 cash price, "which is what a long regulatory close does to an arbitrage spread. A 2027 close will do that." The hosts' framing of the balance sheet was the whole point: "12 times trailing free cash flow at one turn of leverage, got itself a buyer at a premium." Why it matters: a strategic buyer just put a premium price on Alzheimer's-imaging assets, on a clean balance sheet. That is a real-world data point for how the market values the picks-and-shovels layer of the Alzheimer's build-out, the scanners and tracers that every anti-amyloid and anti-tau drug depends on to diagnose and monitor patients.

Eli Lilly had a huge week, and none of it was about Kisunla. The same Telltales episode ran Lilly's "same week in reverse." Lilly agreed to "plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act and pay roughly $800 million over how it promoted Zyprexa," a decades-old antipsychotic, not an Alzheimer's drug. In the same seven days it announced deals to "buy three vaccine and infectious disease companies for $3.8 billion," put "$50 million up front into a CureVac mRNA cancer partnership worth up to $1.8 billion," and "raised full year revenue guidance to $85 to $87 billion." The $800 million fine, the hosts noted, "sits against $21 billion of trailing free cash flow... That's about two weeks of production." Their read: this is "Lilly buying a second act while GLP-1 is still paying for everything." Why it matters here: Lilly owns Kisunla, the donanemab Alzheimer's drug this newsletter tracks, and once again Kisunla did not rate a single mention. Lilly's story this week was weight-loss cash funding a vaccine expansion, with Alzheimer's nowhere in the frame.

The "it's not just amyloid" science got two fresh airings, no company news, but it feeds the debate. Two August 20 science podcasts, just outside the strict window, dug into non-amyloid theories of the disease. On the Gladden Longevity Podcast ("Unraveling Alzheimer's: The Pathobiome Connection," Ep. 353, Aug 20), whose guests are researchers from the Alzheimer's Pathobiome Initiative, the argument was that infections and microbes (oral bacteria like Porphyromonas gingivalis, the respiratory bug Chlamydia pneumoniae, and herpes viruses) may be "accelerants" of Alzheimer's. Their most striking claim: amyloid plaques "are, in fact, antimicrobial in nature... They're a part of the innate immune system, and they are recruited in response to herpetic viruses and other infectious agents." In plain terms: the plaque the drugs are trying to clear may be, in part, the brain fighting off a bug. They flagged that the National Institute on Aging "has given a $49 million grant to study a drug that would essentially target the virulence factor for the P. gingivalis," and cited a Kaiser Permanente study of 500,000 women showing "a 50% reduction in dementia in the group that got any form of hormone replacement." Separately, on Alzheimer's Breakthrough with Dr. Josh Helman, MD ("The Hidden Link Between Your Arteries & Alzheimer's Risk," Aug 20), integrative physician Dr. Daniel LaPerriere, a functional-medicine clinician who treats dementia patients, made the case that poor blood flow is an under-appreciated driver, noting that cerebral blood flow (how much blood reaches the tiny vessels deep in the brain) "goes down by around 0.4% per year from middle age" as we age. Why it matters: neither is investable news, but both reinforce the bear case on amyloid. If plaque is partly a defense, and the real drivers include infection, blood flow, and hormones, then clearing amyloid may keep disappointing on the only question that ultimately matters: does the patient actually get better?

The provocation of the week: "Amyloid beta plaques are, in fact, antimicrobial in nature," per an Alzheimer's Pathobiome Initiative researcher on the Gladden Longevity Podcast, Aug 20. If that turns out to be even partly right, the entire clear-the-plaque franchise is, in some patients, fighting the brain's own immune system.

The debate

Does under-the-skin dosing plus cheap blood tests plus broader coverage finally turn anti-amyloid (and eventually anti-tau) into a multi-billion-dollar franchise, or do modest benefit, brain-bleed risk, and diagnostic bottlenecks keep uptake weak while the tau bets stay unproven?

Bull: The infrastructure keeps getting built, and this week it got validated with cash. A strategic buyer paid a premium (about 15 times trailing cash flow, roughly $8 billion) to take out Lantheus right as the FDA approved its tau scan. That is real money betting on the tools that make an anti-amyloid and anti-tau franchise diagnosable and trackable. And a reliable, approved tau PET tracer is precisely what the next wave of tau drugs needs: you cannot run a clean tau trial, or select the right patients, if you cannot reliably see tau in a living brain. Money follows infrastructure, and the infrastructure is being funded and bought.

Bear: Look hard at what the deal is. It is an imaging-and-diagnostics company being acquired, not a drug selling well. For weeks the podcasts have produced no Kisunla launch numbers, no Leqembi ramp, and no coverage decision. And the only drug-adjacent science this week said amyloid plaque might be the brain's defense against infection, while pointing at blood flow and hormones as real drivers. If the amyloid drugs keep underwhelming and the true action is infection, vascular, or hormonal, then a shiny new tau scan just tells you where the tangles are. It does not tell anyone what to do about them, and no approved tau drug exists yet to act on the picture.

Net: For the first time in a month, this space produced a hard, dollar-denominated event, but it was M&A in the imaging layer, not commercial traction in the drugs. The tau tools are arriving ahead of the tau drugs. Nothing this week moved the trial data or the sales numbers; the referees that decide how big this franchise gets, Kisunla and Leqembi sales prints, a clean Medicare path, and actual tau-drug readouts, are all still ahead.

Stocks in play

The one real corporate event was in imaging. Everything is flagged for what it is.

  • LNTH (Lantheus), the week's main event. Bull: got taken out at a premium on a clean, essentially debt-free balance sheet, and its newly approved tau scan (TAUKLARIFY) is first-mover infrastructure for the tau era. Bear: the stock is now effectively a merger-arbitrage instrument, trading below the $102.50 cash price because the deal does not close until the first half of 2027, with the only extra upside being milestone CVRs (up to $12 a share) that pay only if targets are hit. Next catalyst: Lantheus shareholder vote and regulatory clearances into 2027; early TAUKLARIFY launch uptake. (Telltales)
  • LLY (Eli Lilly). Bull: the GLP-1 engine is strong enough to raise full-year revenue guidance to $85 to $87 billion and fund a vaccine second act; the $800 million Zyprexa fine is a rounding error against $21 billion of free cash flow. Bear: Kisunla remains invisible in the podcasts, so Alzheimer's is still a call option in the story, not a driver. Next catalyst: actual Kisunla patient-start or infusion data. (Telltales)
  • GEHC (GE HealthCare), read-through only. Bull: the Curium and Lantheus deal and the TAUKLARIFY approval validate the amyloid and tau PET-imaging market that GE also competes in. Bear: a rival just consolidated a strong tracer portfolio under Curium. (read-through from Telltales)
  • Curium, the acquirer, and it is private. Named as the buyer putting a premium on Alzheimer's-imaging assets. Not investable in public markets, but a useful signal of what a strategic player will pay for this layer. (Telltales)

Read-throughs

  • PET imaging (LNTH, GEHC): the imaging layer was just repriced by an $8 billion acquisition and handed a new FDA-approved tau tracer in the same fortnight (Telltales). The investable read: the market values these see-the-target assets at a premium and is willing to consolidate them, good for anyone who owns the scanners and dyes, and a reminder that the diagnostic plumbing is maturing faster than the drug commercialization it is meant to serve.
  • Tau-drug developers (Roche/UCB bepranemab, Lilly remternetug, Eisai/Biogen E2814, and others): a reliable, FDA-approved tau PET tracer is a quiet tailwind for all of them, because it makes tau trials cleaner to run and easier to read. The toolkit for the tau era just got a piece it was missing.
  • Non-amyloid mechanisms (infection, vascular, hormonal): got real airtime, with a capital signpost, the $49 million NIA grant for a P. gingivalis-targeting drug and the Kaiser hormone-replacement finding (Gladden Longevity; Alzheimer's Breakthrough). Still years from anything investable, but it is where the amyloid-is-not-the-whole-story money and curiosity keep pointing.

What changed vs last week

Last week was a debate week: two memory specialists and a well-known skeptic arguing about blood tests and drug efficacy, with no hard facts to price. This week flipped to a facts week, with a real acquisition, a real FDA approval, and real Lilly numbers (Telltales).

And the efficacy debate got reinforced from an unexpected direction. Last week the bear case was modest benefit for the risk and cost. This week the pathobiome researchers went a step further: if amyloid plaque is antimicrobial, the brain's own defense, then clearing it is not just low-reward, it might occasionally be counterproductive (Gladden Longevity). That is the most provocative version of the wrong-target argument the newsletter has captured.